{"id":"inf108f-probiotic","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (bloating, gas, abdominal discomfort)"},{"rate":null,"effect":"Transient bacteremia (rare, in immunocompromised patients)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a probiotic therapeutic, INF108F contains live bacterial strains designed to restore beneficial microbiota composition and function. The organism produces metabolites and engages with intestinal epithelial and immune cells to enhance barrier function, promote regulatory T cell differentiation, and reduce pro-inflammatory responses. This mechanism aims to treat conditions driven by dysbiosis and aberrant immune activation.","oneSentence":"INF108F is a live biotherapeutic probiotic that modulates the gut microbiome to promote immune tolerance and reduce intestinal inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:48:43.815Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (marketed/pipeline indication)"}]},"trialDetails":[{"nctId":"NCT05793112","phase":"PHASE4","title":"INF108F in Infants With Food Protein Induced Proctocolitis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-09-09","conditions":"Infant Development, Gut Microbiome, Food Protein Induced Allergic Proctocolitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36518,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"INF108F probiotic","genericName":"INF108F probiotic","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INF108F is a live biotherapeutic probiotic strain that modulates the gut microbiome and immune system to promote health. Used for Clostridium difficile infection (CDI) or related gastrointestinal conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}